证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-007 黑龙江珍宝岛药业股份有限公司 关于控股股东拟办理非公开发行可交换公司债券 股份补充质押的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至 2026 年 2 月 2 日，黑龙江珍宝岛药业股份有限公司（以下简称"公 司"）控股股东黑龙江创达集团有限公司（以下简称"创达集团"）持有公司股份 530,561,726 股，占公司总股本的 56.38%，其累计质押公司股份数量 427,276,426 股，占所持公司股份数量的 80.53%，无一致行动人。 ● 创达集团拟将持有的 1,170,000 股公司股份（占公司总股本的 0.12%， 占创达集团所持公司股份数量的 0.22%）办理补充质押，用于对债券持有人交换 股份和黑龙江创达集团有限公司-2023 年面向专业投资者非公开发行可交换公 司债券（第二期）（以下简称"23 创 02EB"）本息偿付提供担保。 ● 本次补充质押登记办理完成后，创达集团累计质押公司股份数量为 428, ...

Group 1 - The company stated that its stock price fluctuations are influenced by multiple factors including macroeconomic environment, industry policies, and market sentiment [1] - The company indicated that it is unable to predict stock price trends [1]

Group 1 - The company, Zhenbao Island (603567), reported that as of January 30, 2026, the number of A-share shareholders is 29,044 [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-006 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第一期可 交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码为"137171"，发行规模 9.1 亿元，债券 期限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的 临 2023-019 号公告。 二、控股股东可交换公司债券本次换股价格调整情况 2026 年 2 月 3 日 根据《黑龙江创达集团有限公司 202 ...

Core Viewpoint - Zhenbaodao Pharmaceutical is experiencing robust production growth across its manufacturing bases, driven by strong market demand and a well-structured supply chain that enhances its competitive edge in the industry [1][5]. Group 1: Production and Supply Chain - The company's core formulation production lines are operating at full capacity, with a fully booked production schedule for Q1 2026, particularly for cardiovascular and respiratory products [1]. - Zhenbaodao has established GAP cooperative planting bases in Heilongjiang, Gansu, and Shandong, ensuring consistent quality and cost control of key raw materials through standardized processes and a comprehensive quality traceability system [1]. - The modern logistics system facilitates the efficient transportation of raw materials to the company's processing facilities, where advanced automated production lines operate under centralized control, ensuring precision and efficiency [2]. Group 2: Technological Integration - The integration of SCADA systems allows for real-time monitoring of production processes, ensuring that any deviations from standard values trigger alerts, thus maintaining high consistency across product batches even during full-capacity operations [3]. - The use of MES systems records every batch's process data and quality inspection results, creating a complete digital archive that enhances traceability from raw materials to finished products [2][3]. Group 3: Research and Development - Zhenbaodao is investing in R&D to build a future-oriented product pipeline, focusing on deep development of existing major products and exploring new clinical values [4]. - The company is actively involved in the development of innovative traditional Chinese medicine, biopharmaceuticals, and classic formulations, with recent breakthroughs in antibody-drug conjugates (ADC) for non-Hodgkin lymphoma [4]. Group 4: Competitive Advantage - The company's deep control over key raw materials and standardized production and quality systems provide it with strong operational certainty and profitability resilience amid macroeconomic uncertainties [5]. - Zhenbaodao's comprehensive supply chain model enhances its risk resistance and cost advantages, forming a "moat" that secures market supply and quality safety, laying a foundation for sustainable growth in future industry competition [5].

Core Viewpoint - The performance of A-share pharmaceutical stocks in 2025 shows a mixed outlook, with 283 companies disclosing earnings forecasts, where 160 companies expect profit growth while over 120 companies anticipate profit declines, indicating a significant divergence in the industry [1][3]. Group 1: Profit Growth - Among the 283 pharmaceutical stocks, 160 companies are expected to see a year-on-year increase in net profit, with Sino Medical (688108) leading the pack with a projected increase of over 32 times [1][3]. - Sino Medical forecasts a net profit of 43 million to 50 million yuan for 2025, representing a year-on-year growth of 2,767% to 3,233% [3]. - Other notable companies with significant profit growth include WuXi AppTec, Hanyu Pharmaceutical, and Kangxino, with 65 companies projecting a net profit increase of over 100% [3][4]. Group 2: Profit Decline - Over 120 companies are expected to report a decline in net profit for 2025, with 39 companies facing their first losses since listing, including well-known firms like Zhifei Biological and Zhenbao Island [1][5]. - Zhifei Biological anticipates a net loss of approximately 10.698 billion to 13.726 billion yuan, marking a year-on-year decline of 630% to 780% [6][7]. - The decline in the vaccine sector is attributed to decreased public willingness to vaccinate and increased vaccine hesitancy, leading to significant performance pressure across the industry [7][8]. Group 3: Innovative Drug Companies - Several innovative drug companies are reporting positive trends, with some achieving profitability or significantly reducing losses. For instance, Nocren Pharmaceutical is expected to turn a profit for the first time, projecting a net profit of around 633 million yuan [10]. - Rongchang Biopharmaceutical is also expected to turn a profit, with a projected net profit of approximately 716 million yuan, driven by strong sales of core products [10]. - Companies like Junshi Biosciences and Amgen have not yet achieved profitability but are showing a clear trend of reduced losses, indicating a gradual transition towards commercialization and revenue growth in the innovative drug sector [11].

温永豹：我们启动实施新一轮招商引资"三年行动"，先后引进亿达鸿综合制剂、显东药品加工、德润巨牧鸵鸟养殖深加工等项目，投资1.8亿元建设总占地 面积近500亩的生物医药产业园区，虎林医药企业由5家发展到26家，五年间翻了两番，获得"中国刺五加名城"殊荣；农产品就地加工转换率提升至69.6%。 同时，虎林因地制宜发展新质生产力，中国科学院科学家工作室、中国农业大学教授工作站相继落户，全省首家中药领域院士工作站正式授牌，珍宝岛药业 入选国家技术创新示范企业，虎林生物医药产业集群晋升省级中小企业特色产业集群，科技创新走在全省县域前列。 接下来，虎林将落实省新一轮重点产业链高质量发展行动，全力做强生物医药、绿色食品两大核心产业，重点实施"刺五加+"战略，支持珍宝岛药业、乌苏 里江制药等头部企业增型转产，鼓励全乐制药、亿达鸿药业等成长企业增量扩产，推进中鑫生物低分子精品肝素钠等新建项目早完工、早投产，实体化运 行"借澳出海"公司，加快虎林刺五加地理标志商标和地理标志保护产品申报进程，构建"医药+食品+保健+美妆+日用品"全维度产业生态。力争2030年刺五 加种植总量达到32万亩、加工企业发展到15家、产品突破60种、产业 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-005 黑龙江珍宝岛药业股份有限公司 2025年度业绩预告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●本期业绩预告适用于净利润为负值的情形。 ●黑龙江珍宝岛药业股份有限公司（以下简称"公司"）预计2025年度实 现归属于上市公司股东的净利润约为-117,300万元到-101,200万元，与上年同 期相比，将出现亏损。 ●公司预计2025年度实现归属于上市公司股东的扣除非经常性损益的净利 润约为-123,400万元到-107,300万元。 一、本期业绩预告情况 （一）业绩预告期间：2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，公司预计2025年度实现归属于上市公司股东的净 利润约为-117,300万元到-101,200万元，与上年同期相比，将出现亏损。 （三）本期业绩预告为公司根据经营情况的初步测算，未经注册会计师审 计。 二、上年同期业绩情况 （一）利润总额：52,347.19万元。 （二） ...

南财智讯1月30日电，珍宝岛发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润约 为-117,300万元到-101,200万元，与上年同期相比，将出现亏损；预计2025年全年归属于上市公司股东 的扣除非经常性损益的净利润约为-123,400万元到-107,300万元。本期业绩预亏的主要原因：受国家医 药行业政策调整影响，全国中成药集中采购执标时间延后，叠加医保控费力度加大等多重因素，公司本 年度主要产品销售未达预期。1、报告期内，公司主要产品销量未达预期，部分产品单价下降，导致收 入同比下降53%，毛利同比下降93%；2、公司本年度受部分客户回款延迟因素影响导致信用减值损失 约39,468万元；3、公司本年度因存货可变现价值减少导致资产减值损失约26,648万元。 ...

证券之星消息，1月29日中药板块较上一交易日上涨0.98%，片仔癀领涨。当日上证指数报收于4157.98， 上涨0.16%。深证成指报收于14300.08，下跌0.3%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流入1210.05万元，游资资金净流出9243.6万元，散户资金 净流入8033.56万元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600436 | 片仔瘦 | 2.4216 | 11.07% | -9063.85万 | -4.15% | -1.51 Z | -6.92% | | 600085 | 同仁堂 | 5722.98万 | 9.44% | -1391.28万 | -2.30% | -4331.71万 | -7.15% | | 600771 | 广营远 | 4647.58万 | 12.43% | -2690.82万 | -7.20% | - ...